feedzop-word-mark-logo
searchLogin
Feedzop
homeFor YouUnited StatesUnited States
You
bookmarksYour BookmarkshashtagYour Topics
Trending
Terms of UsePrivacy PolicyAboutJobsPartner With Us

© 2026 Advergame Technologies Pvt. Ltd. ("ATPL"). Gamezop ® & Quizzop ® are registered trademarks of ATPL.

Gamezop is a plug-and-play gaming platform that any app or website can integrate to bring casual gaming for its users. Gamezop also operates Quizzop, a quizzing platform, that digital products can add as a trivia section.

Over 5,000 products from more than 70 countries have integrated Gamezop and Quizzop. These include Amazon, Samsung Internet, Snap, Tata Play, AccuWeather, Paytm, Gulf News, and Branch.

Games and trivia increase user engagement significantly within all kinds of apps and websites, besides opening a new stream of advertising revenue. Gamezop and Quizzop take 30 minutes to integrate and can be used for free: both by the products integrating them and end users

Increase ad revenue and engagement on your app / website with games, quizzes, astrology, and cricket content. Visit: business.gamezop.com

Property Code: 5571

Home / Health / Cadaver Fat: The Newest Cosmetic Trend?

Cadaver Fat: The Newest Cosmetic Trend?

3 Feb

•

Summary

  • Cadaver-derived fat is used as an injectable filler for body enhancement.
  • The AlloClae procedure is marketed by Tiger Aesthetics for cosmetic improvements.
  • Risks include fat necrosis, infection, and potential mammogram interference.
Cadaver Fat: The Newest Cosmetic Trend?

A new cosmetic trend in the United States involves using injectable filler derived from cadaver fat for body enhancements, primarily targeting breasts, hips, and buttocks. This procedure, branded as AlloClae and marketed by Tiger Aesthetics, appeals to individuals seeking volume enhancement without traditional surgery.

The fat is sourced from organ and tissue donors, then processed to remove all cells and DNA, preventing immune responses. This acellular fat matrix is often chosen by patients who have undergone liposuction or experienced significant weight loss from medications like Ozempic.

This in-office procedure, often completed in under an hour, offers convenience with minimal downtime and no need for general anesthesia. However, costs can range significantly, from $10,000 to $100,000, depending on the volume injected.

Medical professionals highlight risks such as fat necrosis, infection, and fat embolism. There are also concerns that injecting this material into breast tissue could complicate cancer screenings. Ethical debates question the claim of 'ethical sourcing' for elective cosmetic purposes.

Disclaimer: This story has been auto-aggregated and auto-summarised by a computer program. This story has not been edited or created by the Feedzop team.
AlloClae is a cosmetic procedure in the US that uses injectable filler derived from processed cadaver fat to enhance breasts, hips, and buttocks.
Potential risks include fat necrosis, infection, and fat embolism, and it may complicate mammograms and cancer screenings.
Patients opt for this procedure due to convenience, minimal downtime, and the avoidance of aggressive surgery or general anesthesia, especially if they lack sufficient natural fat.

Read more news on

Healthside-arrow
trending

Anthropic AI triggers 'SaaSpocalypse'

trending

HAL out of stealth jet

trending

India U19 World Cup Semi

trending

IT index plummets

trending

Tanker stalls Mumbai-Pune expressway

trending

Yuki Bhambri achieves milestone

trending

ChatGPT outage reported today

trending

2026 Winter Olympics details

trending

HDFC Bank share price target

You may also like

Tiger Calendar: Majestic Yet Vulnerable

24 Jan • 6 reads

article image

Sustainable Fashion: Armedangels Embraces Spinnova Fiber

17 Dec, 2025 • 211 reads

article image

Serengeti Rains Fuel Bigger Wildfires

17 Dec, 2025 • 272 reads

article image

Hardware Haven: Mitre 10's Summer Gear Shocks Shoppers

9 Dec, 2025 • 255 reads

article image

Brazil's COP30: High Hopes Dashed, Fossil Fuels Sidestepped

23 Nov, 2025 • 394 reads

article image